Neuromodulators
BOTOX:
Botox is an injectable neurotoxin that can help reduce the appearance of fine lines and wrinkles. Botox contains botulinum toxin, which works as a muscle relaxer and blocks the signals that cause the muscles to contract. With the precision and care that Dr. Day uses during the injection process, patients are left with a more youthful, refreshed, and appropriate look.
DYSPORT:
Dysport is another neuromodulator, which uses a form of onabotulinum toxin type A, which works to block the nerve signals telling muscles to contract, allowing for a desired smoothing effect. Different from Botox or Xeomin, Dysport’s unique properties allow it to spread over a larger radius. Additionally, Dysport is frequently used to treat dynamic wrinkles in patients. These dynamic wrinkles are formed because of repetitive muscle movements and can quickly be smoothed by Dysport. The dynamic wrinkles and expression lines, such as crow’s feet and frown lines can be smoothed by Dysport with minimal side effects and downtime.
XEOMIN:
Why Xeomin? Xeomin is a neuromodulator similar to Botox and Dysport; however, Xeomin is without additives and includes the pure form of botulinum toxin type A. During processing, certain proteins are removed. With no additives and no additional proteins, Xeomin reduces the chance that the product will produce an allergic reaction (although already extremely rare) and decrease the likelihood of your body developing antibodies and rejecting the product. Additionally, Xeomin can be used for patients who want a softer look and will appreciate the facial muscle freedom that Xeomin allows, while still reducing fine lines and wrinkles.
JEUVEAU:
Jeuveau is the newest neurotoxin available, receiving the FDA stamp of approval in February 2019. Jeuveau is a 900kDa purified botulinum toxin formula type A and can reduce the appearance of fine lines and wrinkles. Jeuveau is the only neurotoxin available for aesthetic use only and can provide temporary improvement for frown lines. It is a precise product and is wonderful for targeting a specific area.
Estrogen Study
This study is being done to see whether applying a cream with estradiol (a form of estrogen) to the face can improve overall skin quality and help reduce fine lines and wrinkles in peri- and post-menopausal women, and how this relates to epigenetic changes in the skin. A part of the study will also include applying an extra rapamycin analog cream to the face, which is also believed to improve overall skin quality and help reduce fine lines and wrinkles.
WHY THIS MATTERS
Skin aging in peri- and post-menopausal women is deeply tied to hormonal shifts. This study explores whether topical estradiol can turn back the clock – cellularly.
Eligibility
You MAY qualify if you can answer YES to all:
I am a healthy female (peri or menopausal) between the ages of 40 and 65.
I have not had any cosmetic facial treatments in the last 1-3 months.
I have not had any GLP-1 treatments in the last 6 months.
Study Design and Duration
The study includes daily evening application of study cream for 12 weeks, followed by 4 weeks with no test product use. In total, the study will last 16 weeks or approximately 4 months.
Topical Scalp Serum Containing RLX‑201 in Subjects With Mild‑to‑Moderate Hair Thinning
Purpose of the Study
The purpose of this study is to evaluate the safety, tolerability, and effectiveness of a scalp serum containing RLX‑201 when applied once daily for 20 weeks in men and women with mild‑to‑moderate hair thinning. The study will assess changes in hair density, hair thickness, and overall scalp health using clinical evaluations, imaging tools, and participant self‑assessments.
Eligibility
You MAY qualify if you can answer YES to all:
I am a healthy male or female between the ages of 30 and 50.
Self‑perceived mild‑to‑moderate hair thinning.
I have NOT used minoxidil, light therapy, or other hair growth treatments within 3 months.
I have NOT used medications affecting hair growth (e.g., finasteride, spironolactone, cyproterone acetate, 5‑alpha‑reductase inhibitors) or a GLP-1 within 6 months.
Study Design and Duration
This is a single‑center clinical study lasting approximately 20 weeks. If you agree to participate, you will be asked to attend study visits at the following time points: Baseline, and Weeks 2, 4, 8, 12, 16, and 20.